ArticleJournal of leukocyte biology2026
SHIP blocks (MDP + LPS)-induced synergy in macrophages independent of catalytic activity.
Article in Journal of leukocyte biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Macrophages coordinate cytokine responses by integrating signals from pattern recognition receptors including NOD2 and TLR4. NOD2 detects muramyl dipeptide derived from bacterial peptidoglycan, and TLR4 recognizes lipopolysaccharide in the outer membrane of Gram-negative bacteria. NOD2 and TLR4 signals synergize to enhance cytokine production in myeloid cells. While synergy can support host defense, it must be regulated to minimize the risk of excessive inflammation. The lipid phosphatase SHIP, a negative regulator of Class I PI3Ks, reduces inflammatory signaling, but its role during NOD2-TLR4 co-stimulation remains undefined. We found that SHIP limits IL-1β production by blocking synergy in bone marrow-derived macrophages co-stimulated with muramyl dipeptide and lipopolysaccharide. SHIP-/- macrophages showed a synergistic increase in IL-1β that was not evident in SHIP+/+ macrophages. Moreover, reducing SHIP protein concentrations by differentiation in different growth factors, IL-4 treatment, or siRNAs enabled synergy for IL-1β production in SHIP+/+ macrophages. Pharmacologic inhibition of SHIP's catalytic activity did not promote synergy, and similarly, blocking PI3K had no effect, suggesting that the response is independent of SHIP's phosphatase activity. Synergy for IL-1β production was dependent on NOD2 signaling despite NOD2 stimulation alone resulting in little to no IL-1β. Moreover, IL-1β was selectively enhanced in SHIP-/- macrophages during co-stimulation with MDP and LPS, or when MDP stimulation preceded LPS. These findings identify SHIP's adaptor function as a negative regulator of IL-1β induced by NOD2-TLR4 co-stimulation in macrophages, and suggest that SHIP acts as a gatekeeper for macrophage IL-1β during early innate immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.